US President Trump touts success of psychedelic drugs following EO signed in April, specifically Ibogaine (PBM)

Full Post: "In April, I signed a very important Executive Order to accelerate medical treatments for serious mental illness — Specifically, psychedelic drugs, including IBOGAINE. This is something that has helped so many of our amazing VETERANS and true American Heroes who were here in the Oval Office with me, and Joe Rogan. Today I am announcing that Secretary Kennedy has received a Historic Gift from the University of Miami, who has given the Federal Government its original 1994 Ibogaine Investigational New Drug application. This will give everyone direct access to the foundational FDA authorization to accelerate its development as a medical treatment in the U.S. This is HUGE! Special THANK YOU to the University of Miami, who has done this to ensure that Americans are helped as quickly as possible. This adds to the INCREDIBLE PROGRESS since April, including huge amounts of HHS research funding, collaboration between HHS and VA, FDA guidance, and more. We are moving FAST, so that our Veterans with serious mental illness have a RIGHT TO TRY here in the U.S. We hope to see more companies and institutions join us in this very important work. Our Veterans DESERVE it! Thank you for your attention to this matter. President DONALD J. TRUMP"

Executive attention to a specific drug class has historically mattered less for the announcement itself than for the regulatory machinery it sets in motion, and the concrete mechanism here is the handover of an existing Investigational New Drug application, which gives federal agencies and private sponsors a foundational FDA file to build on rather than starting from scratch. The actors are familiar from prior episodes of this administration's health policy: an executive order directing acceleration, HHS and FDA guidance, VA collaboration, and Right to Try framing, a sequence that in past cases has tended to compress development timelines at the margin without guaranteeing approval outcomes. The read-across for listed names in the psychedelic therapeutics space follows an established pattern: headline-driven moves in small-cap drug developers on political endorsement have repeatedly faded absent subsequent FDA scheduling or trial design action, since it is the agency and not the White House that controls the approval channel. Worth noting is the distinction between rescheduling or expanded access, which the executive can genuinely accelerate, and full approval, which remains data-dependent. The follow-ons are agency-level: any DEA scheduling review of the compound, FDA guidance updates, and whether VA research collaboration produces protocol announcements rather than funding headlines.